The efficacy of sustained-release chitosan microspheres containing recombinant human parathyroid hormone on MRONJ

dc.authoridTAYSI, NURI MERT/0000-0002-5595-9302
dc.authoridAtalay, Berkem/0000-0003-3813-7398
dc.authoridErten Taysi, Aysegul/0000-0002-9156-9109
dc.authoridCevher, Erdal/0000-0002-0486-2252
dc.authoridOlgac, Vakur/0000-0003-0497-0314
dc.contributor.authorTaysi, Aysegul Erten
dc.contributor.authorCevher, Erdal
dc.contributor.authorSessevmez, Melike
dc.contributor.authorOlgac, Vakur
dc.contributor.authorTaysi, Nuri Mert
dc.contributor.authorAtalay, Berkem
dc.date.accessioned2025-02-06T17:58:20Z
dc.date.available2025-02-06T17:58:20Z
dc.date.issued2019
dc.departmentAltınbaş Üniversitesien_US
dc.description.abstractTreatment of patients with bisphosphonate usage is a significant concern for oral surgeons because it interferes with jaw bone turnover and regeneration. In case of adverse effects manifesting related to bisphosphonate use, oral surgeons are usually treating and keep the patient's symptoms under control. In this study, we aimed to investigate a new treatment protocol for medication-related osteonecrosis of the jaw (MRONJ). This treatment protocol consisted of administering human parathyroid hormone (hPTH) loaded chitosan microspheres which were prepared by ionotropic gelation method or/and the prepared microspheres were suspended in a poloxamer gel. After in-vitro optimization studies, the efficacy of the chosen formulations was evaluated in-vivo studies. Zoledronic acid was administered daily to forty-eight adult female Sprague-Dawley rats, divided into four experimental groups, at a daily concentration of 0.11 mg/kg over three weeks to induce the MRONJ model. At the end of this period, maxillary left molar teeth were extracted. In the first group, the subjects received no treatment. In the negative control group, poloxamer hydrogel containing empty microspheres were immediately applied to the soft tissues surrounding the extraction socket. The treatment group-1 was treated with local injections of poloxamer hydrogel containing hPTH. The treatment group-2 was treated with a single local injection of poloxamer hydrogel containing hPTH-loaded chitosan microspheres. Both treatment groups received a total of 7 mu g of hPTH at the end of the treatment protocol. Our study demonstrates successful attenuation of MRONJ through a local drug delivery system combined with hPTH, as opposed to previously attempted treatment strategies.en_US
dc.description.sponsorshipScientific Research Projects Coordination Unit of Istanbul University [44564]; [2014/50]en_US
dc.description.sponsorshipThis work was supported by Scientific Research Projects Coordination Unit of Istanbul University [Project Number: 44564]. The present work was performed with the approval of the Animal Rights Committee of Istanbul University (Grant number: 2014/50).en_US
dc.identifier.doi10.1590/1807-3107bor-2019.vol33.0086
dc.identifier.issn1807-3107
dc.identifier.pmid31483052
dc.identifier.scopus2-s2.0-85071772638
dc.identifier.scopusqualityQ2en_US
dc.identifier.urihttps://doi.org/10.1590/1807-3107bor-2019.vol33.0086
dc.identifier.urihttps://hdl.handle.net/20.500.12939/5184
dc.identifier.volume33en_US
dc.identifier.wosWOS:000651227600001
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherSociedade Brasileira De Pesquisa Odontologicaen_US
dc.relation.ispartofBrazilian Oral Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmzKA_WOS_20250206
dc.subjectOsteonecrosisen_US
dc.subjectTeriparatideen_US
dc.subjectChitosanen_US
dc.subjectMicrospheresen_US
dc.titleThe efficacy of sustained-release chitosan microspheres containing recombinant human parathyroid hormone on MRONJen_US
dc.typeArticleen_US

Dosyalar